SUSRF Stock Chart & Stats
$5.41
$0.00(0.00%)
At close: 4:00 PM EDT
$5.41
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.58 - $9.67
Previous CloseN/A
Volume40.00
Average Volume (3M)5.00
Market Cap
$293.88M
Enterprise Value$964.04M
Total Cash (Recent Filing)$658.39M
Total Debt (Recent Filing)$2.86M
Price to Earnings (P/E)31.3
Beta0.16
Next Earnings
Nov 12, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.83
Shares Outstanding51,026,237
10 Day Avg. Volume15
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market Cap3.28
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda4.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.22
Revenue Forecast (FY)$103.38M
Bulls Say, Bears Say
Bulls Say
Revenue And License GrowthStrong Q2 revenue growth combined with a 44% increase in license revenue indicates expanding adoption of the company’s software and content. A higher recurring-style license mix can support more scalable growth, improve economics, and deepen customer relationships over the next several quarters.
Margin ImprovementDelivering a 15% adjusted EBIT margin while gross margin reached 69% demonstrates meaningful operating execution. The improvement reflects stronger license mix, pricing, and simulator operations, creating a foundation for more sustainable profitability as volume and productivity initiatives continue.
Debt-free Balance SheetA debt-free balance sheet and substantial cash position provide financial flexibility to fund product development, facilities, and international expansion without relying on external financing. This resilience should help the company invest through industry cycles while limiting interest and refinancing pressure.
Bears Say
China Structural HeadwindsChina weakness is tied to structural government support for local manufacturers rather than a temporary sales fluctuation. The company is investing in local presence, but the expected multi-quarter response means regional growth and revenue contribution may remain constrained during the outlook period.
Lumpy Revenue TimingDependence on lumpy licenses and development projects can make reported revenue and profitability uneven across quarters, even when underlying demand is healthy. Long lead times increase forecasting uncertainty and may complicate resource planning, making consistent earnings delivery harder to sustain.
Profitability CompressionThe substantial decline in net and gross margins versus earlier periods indicates that recent growth has not translated fully into earnings quality. Although profitability remains positive, sustained margin pressure could limit internal funding capacity and reduce the benefit of future revenue growth.
Surgical Science Sweden AB News
SUSRF FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was $2.58 and its highest was $9.67 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is $293.88M.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Nov 12, 2026 which is in 18 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on Aug 19, 2026. The company reported $0.041 earnings per share for the quarter, missing the consensus estimate of $0.046 by -$0.005.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.07.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of $0.041 in its last earnings report, missing expectations of $0.046. Following the earnings report the stock price went up 24.688%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SUSRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
Technical Analysis
RaySearch Laboratories AB
―
Stille AB
―
OssDsign AB
―
FluoGuide A/S
―
Physitrack Limited
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.90% Public Companies and
Individual Investors